Is the battle over 'skinny' generic labels headed to the Supreme Court?
The US appeals court for the federal circuit recently denied Teva Pharmaceuticals’ request to rehear a case on so-called “skinny” labels that sent shockwaves across the generic drug industry.
That denial means that Teva may shift its appeal to the US Supreme Court, which is a distinct possibility, given how high-stakes this case is, and how it affects almost every generic drug and reference product. Teva did not immediately respond to our request for comment but told other media outlets that it is taking the case to SCOTUS, which experts said may actually hear the case.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
